Ionis Pharmaceuticals
IONS
44.16
+0.16
+0.36%
Ionis Pharmaceuticals
US · IONS
#1749 by market cap
Listed 1970
44.16
+0.16
+0.36%
Live - 5344 symbols - heartbeat 297s ago
· 2026-10-08 04:08
Pre-market
43.88
-0.63%
After-hours
44.16
0.00%
- Market cap
- 7.34B
- P/E (TTM)i
- -12.69
- P/Bi
- 16.69
- EPSi
- -2.38
- Div yieldi
- 0.00%
- 52W posi
- 3%
Reader sentiment
Are you bullish or bearish on IONS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.07, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +33.83% YoY
Margins
- Gross margin
- 98.31%
- Operating margin
- -40.45%
- Net margin
- -40.41%
Key ratios & quality
- Enterprise valuei
- 6.46B
- Altman Z-Scorei
- 1.07
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 599.67M | 1.12B | 729.26M | 810.46M | 587.37M | 787.65M | 705.14M | 943.71M |
| Gross profit | 597.85M | 1.12B | 717.32M | 799.61M | 573.25M | 778.51M | 693.92M | 927.80M |
| Selling & admin expenses | 244.62M | 286.64M | 332.20M | 170.90M | 150.30M | 232.62M | 267.50M | 393.90M |
| Research & development | 414.60M | 465.69M | 535.08M | 643.45M | 833.15M | 899.63M | 901.53M | 915.62M |
| Operating profit | -61.37M | 365.88M | -149.96M | -14.74M | -410.19M | -353.73M | -475.11M | -381.72M |
| Pretax profit | -76.16M | 338.77M | -134.55M | -29.15M | -257.99M | -333.97M | -460.07M | -379.60M |
| Tax | -291.14M | 51.51M | 345.19M | -551.00K | 11.74M | 32.32M | -6.17M | 1.79M |
| Net profit | 214.99M | 287.26M | -479.74M | -28.60M | -269.72M | -366.29M | -453.90M | -381.39M |
| Basic EPS | 2 | 2 | -3 | 0 | -2 | -3 | -3 | -2 |
| Diluted EPS | 2.07 | 1.90 | -3.18 | -0.20 | -1.90 | -2.56 | -3.04 | -2.38 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 131.61M | 452.05M | 156.72M | 203.33M | 246.09M | 267.95M |
| Gross profit | 130.11M | 447.90M | 154.38M | 195.37M | 243.09M | 265.21M |
| Selling & admin expenses | 76.30M | 90.60M | 96.80M | 130.20M | 150.40M | 150.40M |
| Research & development | 200.76M | 217.46M | 217.75M | 279.65M | 210.17M | 217.11M |
| Operating profit | -146.95M | 139.84M | -160.17M | -214.47M | -117.48M | -102.30M |
| Pretax profit | -146.82M | 123.53M | -128.39M | -227.92M | -92.31M | -113.38M |
| Tax | 116.00K | -20.00K | 213.00K | 1.48M | 218.00K | 1.26M |
| Net profit | -146.94M | 123.55M | -128.61M | -229.39M | -92.53M | -114.65M |
| Basic EPS | -1 | 1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.93 | 0.70 | -0.80 | -1.41 | -0.56 | -0.69 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.21B | 2.72B | 2.13B | 2.35B | 2.20B | 2.64B | 2.62B | 2.99B |
| Cash & ST investments | 2.08B | 2.50B | 1.89B | 2.11B | 1.99B | 2.33B | 2.30B | 2.68B |
| Inventory | 8.58M | 18.18M | 21.97M | 24.81M | 22.03M | 7.44M | 12.51M | 10.05M |
| Total assets | 2.67B | 3.23B | 2.39B | 2.61B | 2.53B | 2.99B | 3.00B | 3.52B |
| Total current liabilities | 280.29M | 273.01M | 598.90M | 240.55M | 311.56M | 448.09M | 309.32M | 781.57M |
| Short-term debt | -- | -- | 308.81M | 3.53M | 7.54M | 53.16M | 9.28M | 454.69M |
| Long-term debt | 628.06M | 769.96M | 600.12M | 1.23B | 1.18B | 1.23B | 1.25B | 1.35B |
| Total liabilities | 1,480,624,000.00 | 1,548,565,000.00 | 1,646,473,000.00 | 1,839,953,000.00 | 1,960,989,000.00 | 2,603,386,000.00 | 2,415,324,000.00 | 3,034,747,000.00 |
| Total equity | 1.19B | 1.68B | 743.28M | 771.74M | 572.89M | 386.69M | 588.35M | 489.09M |
| Retained earnings | -967.29M | -707.53M | -1.13B | -1.16B | -1.43B | -1.80B | -2.25B | -2.63B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.42B | 2.58B | 2.52B | 2.99B | 2.94B | 2.49B |
| Cash & ST investments | 2.15B | 2.29B | 2.24B | 2.68B | 1.92B | 2.05B |
| Inventory | 11.50M | 8.48M | 10.47M | 10.05M | 5.56M | 50.83M |
| Total assets | 2.81B | 2.99B | 3.03B | 3.52B | 3.45B | 2.99B |
| Total current liabilities | 250.29M | 897.24M | 903.46M | 781.57M | 716.59M | 315.64M |
| Short-term debt | -- | 630.12M | 630.91M | 454.69M | 432.50M | -- |
| Long-term debt | 1.25B | 625.49M | 595.91M | 1.35B | 1.35B | 1.35B |
| Total liabilities | 2,337,222,000.00 | 2,353,409,000.00 | 2,415,124,000.00 | 3,034,747,000.00 | 2,958,555,000.00 | 2,554,764,000.00 |
| Total equity | 475.73M | 631.72M | 617.97M | 489.09M | 491.41M | 439.74M |
| Retained earnings | -2.40B | -2.27B | -2.40B | -2.63B | -2.72B | -2.84B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 602.91M | 345.63M | 35.89M | 30.80M | -274.37M | -307.51M | -500.95M | -268.58M |
| Depreciation & amortization | 12.53M | 15.99M | 17.16M | 19.56M | 22.11M | 22.50M | 21.99M | 22.69M |
| Free cash flow | 585.25M | 309.35M | -5.16M | 12.90M | -294.47M | -335.50M | -551.29M | -325.67M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 475.87M | 85.27M | -38.51M | 11.57M | 6.37M | 49.44M | 522.73M | 192.60M |
| Ending cash balance | 278.82M | 683.29M | 397.66M | 869.19M | 276.47M | 399.27M | 242.08M | 372.26M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -150.78M | 151.34M | -131.44M | -137.71M | -792.82M | 565.53M |
| Depreciation & amortization | 5.40M | 5.45M | 4.50M | 7.34M | 7.45M | 7.64M |
| Free cash flow | -164.00M | 137.07M | -138.37M | -160.37M | -816.07M | 547.30M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 2.24M | 1.29M | 81.26M | 107.82M | 57.30M | 20.26M |
| Ending cash balance | 264.19M | 297.30M | 338.34M | 372.26M | 173.38M | 350.07M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 40.16 | 23.54 | -39.01 | -3.54 | -40.12 | -76.34 | -93.10 | -70.80 |
| ROA %i | 13.88 | 10.05 | -16.06 | -1.14 | -10.48 | -13.26 | -15.15 | -11.69 |
| ROIC %i | 23.81 | 17.32 | -20.00 | -1.45 | -13.58 | -16.40 | -19.28 | -13.98 |
| 5-year avg ROE %i | -7.89 | -1.02 | -1.34 | 5.94 | -4.05 | -27.66 | -50.69 | -56.83 |
| EBIT margin %i | -5.23 | 35.23 | -17.15 | -3.05 | -43.45 | -32.80 | -53.28 | -31.29 |
| FCF / sales %i | 97.59 | 27.56 | -- | 1.59 | -- | -- | -- | -- |
| Current ratioi | 7.88 | 9.97 | 3.56 | 9.75 | 7.07 | 5.90 | 8.47 | 3.83 |
| Quick ratioi | 7.48 | 9.39 | 3.29 | 9.05 | 6.46 | 5.42 | 7.73 | 3.51 |
| Debt / assetsi | 23.54 | 23.81 | 38.03 | 47.90 | 54.04 | 48.61 | 47.16 | 58.59 |
| LT debt / equityi | 59.92 | 52.34 | 80.74 | 161.65 | 237.68 | 362.15 | 239.19 | 329.15 |
| Interest coveragei | -0.70 | 8.11 | -2.78 | -5.62 | -91.14 | -3.42 | -4.45 | -3.50 |
| Revenue CAGR (3Y) %i | 28.34 | 44.41 | 12.35 | 10.56 | -19.42 | 2.60 | -4.53 | 17.12 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | 296.67 | -- | -- | -71.96 | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -118.62 | -59.91 | -40.04 | -70.80 | -67.62 | -105.50 |
| ROA %i | -16.43 | -9.45 | -8.39 | -11.69 | -10.44 | -18.90 |
| ROIC %i | -20.88 | -10.00 | -8.19 | -13.98 | -11.42 | -29.69 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -52.83 | -20.37 | -18.02 | -31.29 | -22.86 | -54.87 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.66 | 2.87 | 2.79 | 3.83 | 4.10 | 7.89 |
| Quick ratioi | 8.73 | 2.61 | 2.51 | 3.51 | 2.78 | 6.70 |
| Debt / assetsi | 50.13 | 47.57 | 49.11 | 58.59 | 59.16 | 53.88 |
| LT debt / equityi | 296.41 | 125.03 | 138.94 | 329.15 | 327.31 | 366.93 |
| Interest coveragei | -4.45 | -2.34 | -2.06 | -3.50 | -2.91 | -5.82 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Ionis operations100.00%
Quote time 2026-10-08 04:08:11 · For reference only, not investment advice and not tailored to your situation.